The popularity of their weight loss treatments has boosted the fortunes of names such as Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) in recent times. However, users of these life-changing treatments have been saddled with an unforeseen side effect: sunken face, or what is popularly known as Ozempic face. Now, the recently listed Swiss skincare company Galderma (SIX:GALD) believes it has the perfect solution for this challenge and a potentially lucrative market: fillers.
A Solution for Ozempic Face?
The rising use of weight loss drugs such as Ozempic is leaving users with gaunt looks. Flemming Ornskov, the CEO of Galderma, believes that the company’s Sculptra skin treatment and other fillers can restore this side effect. Sculptra helps increase the production of collagen, which helps users treat wrinkles and other symptoms of aging.
Galderma is known for its popular brands such as Cetaphil and Alastin. The company’s Swiss-listed shares have jumped by nearly 9% over the past two weeks.
So far, Galderma has initiated a clinical study to evaluate Sculptra and two types of Restylene for the treatment of contour deficiencies as well as for cheek augmentation in GLP-1 patients. The company hopes to release results from this study as early as the end of this year.
Keeping Tabs on NVO
Meanwhile, Novo Nordisk, the name behind Ozempic, is slated to report its first-quarter results tomorrow. Analysts expect the company to generate an EPS of $0.75 on $9.13 billion in revenue for the quarter. In the comparable year-ago period, NVO’s EPS of $0.65 had outpaced estimates by $0.03.
Is NVO a Buy, Sell, or a Hold?
Novo Nordisk’s share price has rallied by nearly 54% over the past year. Overall, the Street has a Moderate Buy consensus rating on the stock, alongside an average NVO price target of $127.93.
Read full Disclosure
